From: Cefmetazole for bacteremia caused by ESBL-producing enterobacteriaceae comparing with carbapenems
Cefmetazole group | Carbapenems group | p value | ||
---|---|---|---|---|
number | 26 | 43 | - | |
male | 12 | 22 | - | |
age | 67.5 | 71.2 | - | |
Source | UTI | 18 (69 %) | 17 (40 %) | - |
Pathogen | E.coli | 25 (96 %) | 39 (91 %) | - |
Outcome | survive without relapse | 25 | 36 | 0.243 |
death | 1 | 5 | ||
relapse | 0 | 2 | ||
Patient profile | SOFA | 2.8 + -2.8 | 5.0 + -4.5 | 0.055 |
Charlson | 7.1 + -3.4 | 6.8 + -2.8 | 0.85 | |
Pitt. Bact. Score | 1.5 + -1.5 | 2.5 + -2.1 | 0.048 | |
admission to ICU | 5 (24 %) | 17 (39 %) | 0.111 | |
community acquired | 10 (38 %) | 11(26 %) | 0.29 | |
Bacterial profile | mixed infection | 2 (8 %) | 7 (16 %) | 0.466 |
cefmetazole:R | 0 (0 %) | 1 (2 %) | 1 | |
fluoroquinolone:R | 19 (73 %) | 34 (79 %) | 1 | |
Treatment profile | ID consult | 19 (73 %) | 21 (49 %) | 0.077 |
empiric cover | 13 (50 %) | 27 (63 %) | 0.325 |